SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-080483
Filing Date
2022-07-18
Accepted
2022-07-18 16:01:33
Documents
13
Period of Report
2022-07-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2221215d1_8k.htm   iXBRL 8-K 26113
2 EXHIBIT 10.1 tm2221215d1_ex10-1.htm EX-10.1 58799
  Complete submission text file 0001104659-22-080483.txt   270828

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cldx-20220715.xsd EX-101.SCH 3066
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cldx-20220715_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cldx-20220715_pre.xml EX-101.PRE 22617
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2221215d1_8k_htm.xml XML 3522
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-15006 | Film No.: 221089214
SIC: 2835 In Vitro & In Vivo Diagnostic Substances